ClinConnect ClinConnect Logo
Search / Trial NCT06293989

Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo

Launched by UNIVERSITY OF MONASTIR · Mar 4, 2024

Trial Information

Current as of August 21, 2025

Not yet recruiting

Keywords

Vertigo Diazepam Placebo

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of two different doses of a medication called diazepam (also known as Valium®) for treating acute peripheral vertigo, which is a sudden spinning sensation that can make it hard to balance. Researchers will compare these doses to a placebo, which is a non-active treatment, to see which option works better in providing relief. The trial will take place in the emergency departments of three hospitals in Tunisia.

To participate in the trial, individuals must be between 18 and 70 years old and have been diagnosed with acute peripheral vertigo by an emergency doctor. However, those over 70 or with certain health issues, such as specific neurological problems or recent use of certain medications, will not be eligible. If you join the study, you can expect to receive either diazepam or a placebo during your visit to the emergency department, and researchers will monitor your response to the treatment. This trial aims to find better ways to help people experiencing this distressing condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria;
  • patients between 18 and 70 years of age
  • a chief complaint of acute peripheral vertigo (APV) (sensation of spinning, which was worsened by movement and sudden in onset) were eligible if the treating emergency physician diagnosed an episode of vertigo that was peripheral in nature.
  • Exclusion Criteria: -Patients aged \> 70 years as central vertigo , -patients with a focal neurologic deficit, pregnancy, history of allergic reaction or contraindication to any of the test drugs, history of enrolment in a previous clinical drug trial,
  • history of recent ingestion (within 24 hours) of a sedative, antihistamine, antipsychotic, or opioid,
  • history of syncope or cardiac event, considerations of a central origin for vertigo -evidence of drug-induced vertigo or orthostatic hypotension -history of mental or neurological illness.

About University Of Monastir

The University of Monastir, a prominent educational and research institution in Tunisia, is dedicated to advancing medical and clinical research through its innovative programs and collaborations. With a strong emphasis on improving healthcare outcomes, the university actively sponsors clinical trials that explore new therapeutic approaches and enhance patient care. Leveraging its state-of-the-art facilities and a diverse team of experienced researchers and clinicians, the University of Monastir aims to contribute significantly to the global body of medical knowledge while fostering a culture of scientific inquiry and excellence.

Locations

Patients applied

0 patients applied

Trial Officials

Nouira semir, Pr

Study Director

University of Monastir

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported